Fibromyalgia: A new treatment option for fibromyalgia

Nature Reviews Rheumatology

Volumn 5, Issue 4, 2009, Pages 188-190

  Bennett, Robert M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; CYCLOPROPANE DERIVATIVE; MILNACIPRAN;

FIBROMYALGIA; HUMAN; NOTE;

ADRENERGIC UPTAKE INHIBITORS; CYCLOPROPANES; FIBROMYALGIA; HUMANS;

EID: 67650477859     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.48     Document Type: Article

References (10)

1. Lawrence, R. C. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 58, 26-35 (2008).
2. Boomershine, C. S. & Crofford, L. J. A symptom-based approach to pharmacologic management of fibromyalgia. Nat. Rev. Rheumatol. 5, 191-199 (2009).
3. FDA Center for Drug Evaluation and Research. Savella (milnacipran) label information [online 8 January 2009], http://www.fda.gov/cder/ foi/label/2009/022256lbl.pdf (2009).
4. Clauw, D. J., Mease, P, Palmer, R. H., Gendreau, R. M. & Wang, Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin. Ther. 30, 1988-2004 (2008).
5. FDA Center for Drug Evaluation and Research. Summary Review for Savella (milnacipran): application #22-256, http://www.fda.gov/ cder/foi/summary review/2009/022256s000SumR.pdf (2009).
6. Mease, P. J. et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo- controlled trial. J. Rheumatol. 36, 398-409 (2009).
7. Mease, P., Palmer, R. H., Rao, S., Zablocki, R. & Qu, P. Improvement in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: results from a dose controlled extension study [abstract #583]. Arthritis Rheum. 58 (Suppl.), S383 (2008).
8. Stahl, S. M., Grady, M. M., Moret, C. & Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10, 732-747 (2005).
9. Heinricher, M. M., Tavares, I., Leith, J. L. & Lumb, B. M. Descending control of nociception: specificity, recruitment and plasticity. Brain Res. Rev. doi:10.1016/j.brainresrev.2008.12.009 (2008).
10. Vaishnavi, S. N. et al. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry 55, 320-322 (2004).